Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Nebraska Medicine Durham Outpatient Center

Actemra

Afinitor

Alecensa

Alunbrig

Ayvakit

Bosulif

Braftovi

Brukinsa

Cabometyx

Calquence

Comteriq

Copiktra

Cotellic

Daurismo

Erivedge

Esbriet

Exvity

Fasenra

Fotivdo

Gavreto

Gilotrif

Idhifa

Ibrance

Iclusig

Ilumya

Imbruvica

Inlyta

Inrebic

Inqovi

Iressa

Jakafi

Koselugo

Lenvima

Lonsurf

Lorbrena

Lumakras

Lynparza

Lytgobi

Matulane

Mavenclad

Mekinist

Mektovi

Nexavar

Odmozo

Ofev

Olumiant

Piqray

Retevmo

Rozlytrek

Rubraca

Siliq

Stelara

Stivarga

Sutent

Yasigma

Tabrecta

Tafinlar

Tagrisso

Tarceva

Tazverik

Tibsovo

Truseltiq

Venclexta

Verenzio

Vizimpro

Vitravki

Vonjo

Votrient

Welireg

Xalkori

Xolair

Xospata

Xpovio

Xtandi

Yonsa

Zejula

Zelboraf

Zydelig

Zykadia

Rinvoq | Nebraska Medicine Durham Outpatient Center

Does Nebraska Medicine Durham Outpatient Center work closely with Rinvoq and AbbVie Inc.?

Does Nebraska Medicine Durham Outpatient Center offer services for Rinvoq patients?

What conditions does Nebraska Medicine Durham Outpatient Center support?

How does Nebraska Medicine Durham Outpatient Center help with insurance?